Market Cap 106.91M
Revenue (ttm) 107.88M
Net Income (ttm) -33.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.07%
Debt to Equity Ratio -6.30
Volume 216,200
Avg Vol 144,830
Day's Range N/A - N/A
Shares Out 49.50M
Stochastic %K 2%
Beta 1.73
Analysts Strong Sell
Price Target $7.75

Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 866 259 5644
Address:
CAP Business Center, Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts, Herstal, Belgium
UngenauOrange
UngenauOrange Apr. 5 at 4:38 PM
$MDXH @thecontracap @nbix16 @slick3333 There is a detail in the q4 press release about the fair value adjustment of 2,178m. It sais "1) Primarily related to GPS and ExoDx contingent considerations, option to pay Bio-Techne and Exact Sciences earnout in shares, and prepayment right of the OrbiMed loan" So the earnout payments not only got stretched out but also allow for payment in stock now. On the one hand it reduces that debt risk to the company but on the others we may face dilution which makes me agree with @nbix16 about ATM usage even more. Can anybody contribute to what this means? I'm not sure I fully understand.
0 · Reply
thecontracap
thecontracap Apr. 3 at 6:11 PM
$MDXH painful decline last 2 weeks, no doubt. I think mismanagement of expectations and technicals vs anything truly fundamental. I expect 25mm EBITDA in 27 and 35+ in 2028. Within 12 months, if we are tracking there, this should trade 10-15x 28 EBITDA conservatively. 350mm- 500mm EV. 120mm net debt. 230mm-380mm mkt cap. /55mm shares $4-7/sh. Best guess is they look to sell at that point. Michael is 63 and looking for the finish line. 3x rev very reasonable. 600mm EV. 480mm mkt cap. $8.75/sh. Annoyed I got run over on my large $3 purchase a couple weeks ago, but I’m looking to add down here. Talking to Michael on 4/6.
1 · Reply
UngenauOrange
UngenauOrange Mar. 30 at 6:27 PM
$MDXH Jesus. I may have to buy more :(
0 · Reply
nbix16
nbix16 Mar. 25 at 7:19 PM
$MDXH remain extremely bullish on the stock but I hope this arrogant ass McGarrity has learned why you should tap an ATM when the stock has rocketed 100% and you know you'll need cash at some point. Such arrogance it's baffling
0 · Reply
slick3333
slick3333 Mar. 21 at 5:55 AM
$MDXH we break below 3 next week sigh…..down the dumps we go again!
0 · Reply
slick3333
slick3333 Mar. 13 at 3:38 AM
$MDXH sigh this one is a slow painful death …two resistance level left 3.12 and 3 and then comes the death spiral
0 · Reply
slick3333
slick3333 Mar. 4 at 12:53 AM
$MDXH looks really bad and we may hit low 2s with mediocre sales and increasing losses ….market only cares about guidance not slow movers that can produce somewhat ok revenue
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 26 at 10:14 PM
$MDXH Q4 '25 Earnings Results & Recap MDxHealth maintains its 2026 revenue guidance of $137M, expecting 27-30% growth. MDxHealth also confirms its view of driving progress toward a 10% adjusted EBITDA margin run rate exiting 2026.
0 · Reply
slick3333
slick3333 Feb. 26 at 9:12 PM
$MDXH dang as usual not the a fantabulous earning report and dump
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 3:13 PM
$MDXH RSI: 54.31, MACD: 0.0006 Vol: 0.10, MA20: 3.58, MA50: 3.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on MDXH
MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 8:07 PM EST - 5 weeks ago

MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript


MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 11:11 PM EST - 5 months ago

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript


Angle PLC Announces Strategy Update

Oct 8, 2025, 2:00 AM EDT - 6 months ago

Angle PLC Announces Strategy Update


MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:57 PM EDT - 11 months ago

MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript


MDxHealth Reports Q1-2025 Results

May 14, 2025, 4:00 PM EDT - 11 months ago

MDxHealth Reports Q1-2025 Results


MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:57 PM EST - 1 year ago

MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript


MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics

Dec 13, 2024, 10:15 AM EST - 1 year ago

MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics


MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:13 AM EST - 1 year ago

MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript


MDxHealth Announces Pricing of Offering of Ordinary Shares

Sep 25, 2024, 9:31 PM EDT - 1 year ago

MDxHealth Announces Pricing of Offering of Ordinary Shares


MDxHealth Announces Launch of Offering of Ordinary Shares

Sep 25, 2024, 4:05 PM EDT - 1 year ago

MDxHealth Announces Launch of Offering of Ordinary Shares


MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript

Aug 22, 2024, 4:34 AM EDT - 1 year ago

MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript


MDxHealth Reports Q2 and Half Year 2024 Results

Aug 21, 2024, 4:00 PM EDT - 1 year ago

MDxHealth Reports Q2 and Half Year 2024 Results


Mdxhealth Appoints Sanford J. Siegel, M.D.

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Mdxhealth Appoints Sanford J. Siegel, M.D.


Mdxhealth to Present at Upcoming Investor Conferences

May 15, 2024, 4:00 PM EDT - 2 years ago

Mdxhealth to Present at Upcoming Investor Conferences


MDxHealth SA (MDXH) Q1 2024 Earnings Call Transcript

May 4, 2024, 11:49 AM EDT - 2 years ago

MDxHealth SA (MDXH) Q1 2024 Earnings Call Transcript


MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:07 PM EST - 2 years ago

MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript


Mdxhealth Announces Resignation of Board Member

Feb 16, 2024, 8:45 AM EST - 2 years ago

Mdxhealth Announces Resignation of Board Member


MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript

Nov 11, 2023, 5:33 PM EST - 2 years ago

MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript


Mdxhealth's New Share Capital Amount and New Number of Shares

Oct 20, 2023, 4:00 PM EDT - 2 years ago

Mdxhealth's New Share Capital Amount and New Number of Shares


MDxHealth Reports Preliminary Q3-2023 Revenues

Oct 9, 2023, 4:00 PM EDT - 2 years ago

MDxHealth Reports Preliminary Q3-2023 Revenues


MDxHealth SA (MXDHF) Q2 2023 Earnings Call Transcript

Aug 23, 2023, 8:41 PM EDT - 2 years ago

MDxHealth SA (MXDHF) Q2 2023 Earnings Call Transcript


MDxHealth Reports Q2 and Half Year 2023 Results

Aug 23, 2023, 4:00 PM EDT - 2 years ago

MDxHealth Reports Q2 and Half Year 2023 Results


UngenauOrange
UngenauOrange Apr. 5 at 4:38 PM
$MDXH @thecontracap @nbix16 @slick3333 There is a detail in the q4 press release about the fair value adjustment of 2,178m. It sais "1) Primarily related to GPS and ExoDx contingent considerations, option to pay Bio-Techne and Exact Sciences earnout in shares, and prepayment right of the OrbiMed loan" So the earnout payments not only got stretched out but also allow for payment in stock now. On the one hand it reduces that debt risk to the company but on the others we may face dilution which makes me agree with @nbix16 about ATM usage even more. Can anybody contribute to what this means? I'm not sure I fully understand.
0 · Reply
thecontracap
thecontracap Apr. 3 at 6:11 PM
$MDXH painful decline last 2 weeks, no doubt. I think mismanagement of expectations and technicals vs anything truly fundamental. I expect 25mm EBITDA in 27 and 35+ in 2028. Within 12 months, if we are tracking there, this should trade 10-15x 28 EBITDA conservatively. 350mm- 500mm EV. 120mm net debt. 230mm-380mm mkt cap. /55mm shares $4-7/sh. Best guess is they look to sell at that point. Michael is 63 and looking for the finish line. 3x rev very reasonable. 600mm EV. 480mm mkt cap. $8.75/sh. Annoyed I got run over on my large $3 purchase a couple weeks ago, but I’m looking to add down here. Talking to Michael on 4/6.
1 · Reply
UngenauOrange
UngenauOrange Mar. 30 at 6:27 PM
$MDXH Jesus. I may have to buy more :(
0 · Reply
nbix16
nbix16 Mar. 25 at 7:19 PM
$MDXH remain extremely bullish on the stock but I hope this arrogant ass McGarrity has learned why you should tap an ATM when the stock has rocketed 100% and you know you'll need cash at some point. Such arrogance it's baffling
0 · Reply
slick3333
slick3333 Mar. 21 at 5:55 AM
$MDXH we break below 3 next week sigh…..down the dumps we go again!
0 · Reply
slick3333
slick3333 Mar. 13 at 3:38 AM
$MDXH sigh this one is a slow painful death …two resistance level left 3.12 and 3 and then comes the death spiral
0 · Reply
slick3333
slick3333 Mar. 4 at 12:53 AM
$MDXH looks really bad and we may hit low 2s with mediocre sales and increasing losses ….market only cares about guidance not slow movers that can produce somewhat ok revenue
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 26 at 10:14 PM
$MDXH Q4 '25 Earnings Results & Recap MDxHealth maintains its 2026 revenue guidance of $137M, expecting 27-30% growth. MDxHealth also confirms its view of driving progress toward a 10% adjusted EBITDA margin run rate exiting 2026.
0 · Reply
slick3333
slick3333 Feb. 26 at 9:12 PM
$MDXH dang as usual not the a fantabulous earning report and dump
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 3:13 PM
$MDXH RSI: 54.31, MACD: 0.0006 Vol: 0.10, MA20: 3.58, MA50: 3.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FadeChaser
FadeChaser Feb. 18 at 9:18 AM
$MDXH Biotech where data consistency is critical; trust once lost is hard to regain.
0 · Reply
HiddenSentiment
HiddenSentiment Feb. 18 at 8:01 AM
$MDXH MDxHealth provides molecular diagnostics, facing test adoption dependent on clinician education and favorable insurance coverage [citation:historical].
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 12:14 AM
$MDXH Current Stock Price: $3.66
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 8:38 AM
$MDXH Brilliant piece that captures MDXH's situation perfectly. So if you want to update your understanding of MDXH or get to know MDXH better, this is essential reading. https://everyticker.com/quote/MDXH/analysis/mdxhealth-mdxh-unlocking-growth-in-urology-diagnostics-with-precision-technology
0 · Reply
Texasstockman1
Texasstockman1 Feb. 3 at 10:57 PM
$MDXH I like the way this company is shaping up. The stability is there, and the demand is real — especially with an aging population that increasingly needs these types of diagnostics. I’m looking for an entry soon, starting small and staying disciplined until they get past ER. Long-term, this space has meaningful upside if adoption continues.
0 · Reply
UngenauOrange
UngenauOrange Jan. 12 at 7:26 PM
$MDXH @slick3333 @nbix16 @thecontracap Two things. a) Regarding the tissue concerns. This reminds me that Veracyte had 27% growth for Decipher last quarter when mdxh was flat. They also said that they try to go more into the low risk patient market. That's where mdxh mostly is afaik. I planned to look into this but never did. Seems like it is a good time to do so now. Do you have insights into this yet? b) Do you guys plan to look into the study from the last press release? I will try to but not sure how to go about it yet. Would love if we could share results and compare notes here.
1 · Reply
slick3333
slick3333 Jan. 12 at 2:49 PM
$MDXH guess preliminary sales not good enough
2 · Reply
HygrometerHue
HygrometerHue Dec. 27 at 12:28 PM
$MDXH Investors are weighing durability against tactical noise; competitive differentiation has to emerge in data — any stumble could quickly widen valuation discounts. Markets will follow data, not narratives.
0 · Reply
RubyRacer
RubyRacer Dec. 27 at 4:36 AM
$MDXH The environment increasingly favors disciplined operators instead of aggressive storytellers. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. The trajectory strengthens as results compound visibly.
0 · Reply
RoboAdvisorR
RoboAdvisorR Dec. 24 at 12:37 PM
$MDXH Future price discovery depends on how timelines compress uncertainty rather than extend speculation. Sustained traction would support a meaningful re-rating.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 11:52 AM
BTIG has adjusted their stance on MDxHealth ( $MDXH ), setting the rating to Buy with a target price of 7.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 19 at 10:03 PM
0 · Reply